Skip to main
LKFT

Lakefront Biotherapeutics (LKFT) Stock Forecast & Price Target

Lakefront Biotherapeutics (LKFT) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Lakefront Biotherapeutics is a well-established biopharmaceutical company with an impressive pipeline and strong partnerships. It has a promising lead drug candidate, gamgertamig, which has shown potential for treating rare autoimmune diseases. The company has a strong balance sheet and its sustainable initiatives reflect its commitment to improving the lives of patients. With numerous potential catalysts in the near future, Lakefront Biotherapeutics appears to be a solid investment opportunity.

Bears say

Lakefront Biotherapeutics is a clinical-stage biotechnology company with a promising platform for target discovery and development of small molecule inhibitors for severe diseases. However, the company's partnerships and speculative nature add uncertainty to its revenue potential, and with a negative EV and lack of visibility in specific therapeutic areas, a neutral view is warranted, especially considering the risks of developing early-stage compounds and the potential need for competitive assets at attractive valuations.

Lakefront Biotherapeutics (LKFT) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lakefront Biotherapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lakefront Biotherapeutics (LKFT) Forecast

Analysts have given Lakefront Biotherapeutics (LKFT) a Hold based on their latest research and market trends.

According to 2 analysts, Lakefront Biotherapeutics (LKFT) has a Hold consensus rating as of Sep 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lakefront Biotherapeutics (LKFT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.